Panacea Biotec shares surged 5% to hit the upper circuit on April 24, 2025, following the announcement of an additional order from UNICEF for the supply of its bivalent oral polio vaccine (bOPV).
This new order supplements an earlier contract communicated on December 24, 2024. At that time, UNICEF had awarded Panacea Biotec a contract for 115 million doses, valued at approximately USD 14.95 million (around Rs.127 crore), scheduled for delivery during the 2025 calendar year.
Under the latest development, Panacea Biotec has secured an additional contract for 40 million doses of bOPV, equivalent to 2 million vials. The value of this new order is approximately USD 5.20 million (around Rs.44 crore). The supply is expected to be executed in the third quarter of 2025.
The order has been placed under the existing long-term arrangement between Panacea Biotec and UNICEF. This arrangement will be updated to reflect the latest award.
Panacea Biotec shares opened at ₹524.00 today, hitting a high of ₹538.55 and dipping to a low of ₹519.10. The stock is trading close to its 52-week high of ₹549.05, a significant rise from its 52-week low of ₹112.35.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
